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A b s t r a c t  
The objective of the study is to evaluate the potential of novel vesicular drug delivery systems for 
drug targeting. Novel vesicular drug delivery systems aim to deliver the drug at a rate directed by 
need of body during the period of treatment, and channel the active entity to the site of action. 
Vesicular drug delivery systems have been used to improve the therapeutic index, solubility, stability 
and rapid degradation of drug molecule. Thus a number of novel vesicular drug delivery systems 
have been developed that allow drug targeting and sustained or controlled release of drug. The 
focus of this review is to discuss various lipoidal and non-lipoidal vesicles with special emphasis on 
targeting of drugs. 
Keywords: Vesicular drug delivery systems, drug targeting, bioavailability enhancement, lipoidal and 
non-lipoidal biocarriers. 
 
Introduction 
Novel vesicular drug delivery systems aim to deliver the drug at a 
rate directed by need of body during the period of treatment, and 
channel the active entity to the site of action. Biologic origin of 
these vesicles was first reported in 1965 by ÂBinghamÊ and has 
been given the name ÂBingham bodiesÊ.  A number of novel 
vesicular drug delivery systems have been emerged encompassing 
various routes of administration, to achieve targeted and controlled 
drug delivery [1].Targeted drug delivery is a mode of delivering the 
therapeutic agent to the tissues of interest while reducing the 
relative concentration of therapeutic agent in remaining tissues 
which improves the therapeutic efficacy and reduces the side 
effects. Drug targeting means the delivery of drugs to receptor, 
organs or any other specific part of body to which one wishes to 
deliver the entire drug [2]. The targeted drug delivery system was 
developed by Paul Ehrlich, in 1909, which delivered the therapeutic 
agent directly to diseased cells. Since then, numbers of carriers 
were utilized to deliver the drug at target site; these include 
immunoglobulins, serum proteins, synthetic polymers, 
microspheres, liposomes, niosomes, erythrocytes etc. Among 
different carriers, vesicular drug delivery systems are found to be 
well renowned [3]. These systems have also been used to improve 
the therapeutic index, solubility, stability and rapid degradation of 
drug molecules [1-4]. In this article, an attempt has been made to 
discuss various types of vesicular drug delivery systems with 
special emphasis on their drug targeting application. 
Types 
The targeted vesicles are classified on the basis of their 
composition (5): 
• Lipoidal biocarriers 
• Non-lipoidal biocarriers 
 
Table 1: Types of vesicles for site specific targeting 
Lipoidal biocarriers for site specific targeting 
1. Liposomes 2. Emulsomes
3. Enzymosomes 4. Ethosomes
5. Sphingosomes 6. Transferosomes
7. Pharmacosomes 8. Virosomes
Non- lipoidal biocarriers for site-specific targeting:
1. Niosomes 2. Bilosomes
3. Aquasomes  
Lipoidal Biocarries for Site Specific Targeting 
Liposomes 
Liposomes are simple microscopic lipid vesicles ranging from 20 
nanometers to several micrometers in size. They have lipid bilayer 
structures, which is present with an aqueous volume entirely 
enclosed by a membrane, composed of lipid molecules in such a 
way that both  hydrophilic and lipophilic drugs can be successfully 
entrapped [1,6,7]. The lipophilic drugs get entrapped within bilayer 
membrane whereas hydrophilic drugs get entrapped in the central 
aqueous core of the vesicles[6]. Liposomes can be used for both 
oral as well as topical drug targeting. They act by the following 
mechanisms [8]. 
They attach to cellular membrane and appear to fuse with them, 
releasing their content into the cell. 
Sometimes they are taken up by the cell and their phospholipids 
are incorporated into the cell membrane by which the drug trapped 
inside is released. 
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In the case of phagocytic cell, liposomes are taken up, the 
phospholipid walls are acted upon by organelles called lysosomes 
and entrapped drug is released. 
A number of components are present in liposomes, with 
phospholipid and cholesterol being the main ingredients[1]. The 
most commonly used natural phospholipid is phosphatidylcholine 
(PC). Some other phospholipids such as phosphatidyl 
ethanolamine (PE), phosphatidyl serine (PS), phosphatidyl inositol 
(PI) and phosphatidyl glycerol (PG) can also be used[9]. 
Cholesterol is added to the bilayer mixture for the following 
purposes[1,8]. 
It acts as a fluidity buffer. 
Provides rigidity and orientational order 
Acts as intercalator with phospholipid molecules 
Decreases the permeability coefficient of negative, neutral as well 
as positively charged membranes to Na+, K+, Cl⎯ and glucose. 
Stabilizes the membrane against temperature changes, leading to 
lower permeability at elevated temperature and impart better 
stability. 
 
 
Table 2: Several types of liposomes with composition and applications 
S. No. Type Composition Applications Reference
1 Conventional 
liposomes (CL) 
Neutral or negatively charged 
phospholipids with cholesterol 
Targeted delivery of antimicrobial 
agent to macrophages, 
vaccination 
[1,10]
2 pH sensitive liposomes Phospholipids such as phosphatidyl 
ethanolamine, 
dioleoylphosphatidylethanolamine  
Tumourtargeting, coated pit 
endocytosis 
 
[1]
3 Cationic liposomes Positively charged cationic lipids Gene delivery [1,8,10]
4 Long circulatory 
(stealth) liposomes 
(LCL) 
Neutral high transition 
temperature,lipid,cholesteroland 5-
10% of PEG (polyethylene glycol) 
Selective targeting topathological 
areas 
[1,10]
5 Immuno-liposomes Conventional or long circulatory 
liposomes with attached antibody or 
recognition sequence 
Subject to receptor mediated 
endocytosis, specific targeting 
[1]
6 Magnetic liposomes Phosphatidylcholine, cholesterol, small 
amounts of linear chain aldehyde and 
colloidal particles of magnetic iron 
oxide 
Specific targeting of antibodies to 
brain 
[1,11]
7 Temperature or heat 
sensitive liposomes 
Dipalmitoylphosphatidyl choline Site specific delivery of drugs for 
the treatment of solid tumours 
[1,7,12]
 
The loading of drugs into liposomes offer an efficient means of 
drug targeting to mononuclear phagocytic system(MPS) cells. As 
particulate carriers, liposomes naturally target cells of the MPS, 
particularly macrophages to treat a number of diseases including 
infectious diseases, inflammatory diseases, cancer and 
atherosclerosis. To achieve targeting of liposomes to monocytes, 
macrophages and dendritic cells, the physicochemical properties of 
liposomes has been modified by addition of surface ligands such 
as proteins, peptides, antibodies, polysaccharides, glycolipids, 
glycoproteins and lectins [11]. Epidermal growth factor receptor 
(EGFR) targeted doxorubicin immunoliposomes have been 
prepared to increase drug delivery to tumours such as breast, 
colon, pancreatic, lungs and ovarian cancers [13].Doijad Rajindra 
C et al prepared zidovudine, loaded liposomes for targeting to liver 
followed by lungs, kidney and spleen against human 
immunodeficiency virus (HIV) [14].Amphotericin-B loaded 
aerosolized liposomes coated with o-palmitoyl mannan were 
prepared by Vyas et al for their selective targeting to lungs 
(alveolar macrophages) for the treatment of fungal diseases in 
lungs [15].Targeted chemotherapy of brain tumor using 
polysaccharide-anchored liposomes loaded with cisplatin has been 
attempted by Ochi et al [16]. 
Emulsomes 
Emulsome is a lipid based drug delivery system, especially 
designed for parenteral delivery of drugs having poor aqueous 
solubility [17]. In emulsomes, the internal core is made up of fats 
and triglycerides, which are stabilized in form of o/w emulsion by 
addition of high concentration of lecithin. Emulsomes have the 
characteristics of both liposomes and emulsions. By virtue of 
solidified or semisolidified internal oily core, it provides better 
opportunity to load lipophilic drugs in high concentration, 
simultaneously a controlled release can also be expected and 
these also have the ability to encapsulate water soluble 
medicaments in aqueous compartments of surrounding 
phospholipids layers. The solvent-free and surfactant-free 
emulsome technologies have demonstrated high encapsulation 
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capacity for water insoluble antifungal and anticancer drugs, 
showed enhanced drug delivery and improved preclinical efficacy 
for oral route [5]. Senthil et al prepared amphotericin B (an effective 
antifungal and anti-leishmanial agent) loaded emulsomes for the 
treatment of visceral leishmaniasis. This study focus on preparing 
macrophage (liver, spleen and bone marrow) targeted emulsomes 
to reduce the adverse effects of conventional treatments [18]. Raza 
et al prepared dithranol loaded emulsomes with enhanced 
biocompatibility, efficacy and stability in treatment of psoriasis [19]. 
Vyas et al developed zidovudine emulsomes for sustained and 
targeted drug delivery to liver for the treatment of life-threatening 
viral infections like hepatitis, HIV and Epstein-Barr virus infection 
[20]. 
Enzymosomes 
The therapeutic proteins like enzymes can be delivered through 
several approaches such as using polymeric carriers; aqueous 
space of lipid and bilayered vesicles but their delivery by 
attachment on surface of liposomes has shown the prominent 
response for the development of antibodies at the target site. 
Enzymes upon complexing with lipids generate enzymosomes. 
Superoxide Dismutase (a therapeutic agent for oxidative stress 
related diseases like rheumatoid arthritis and 
ischaemia/reperfusion situations) loaded enzymosomes have been 
developed with long circulation time in the blood, in order to 
accumulate at inflammed target sites, while maintaining enzymatic 
activity in its intact form [21,22]. 
Ethosomes 
Ethosomes have also been developed for delivering the drugs 
having low penetration power through skin. Ethosomes are soft 
lipid vesicles of size range from tens of nanometers to microns, 
containing phospholipids, alcohol (ethanol and isopropyl alcohol) in 
relatively high concentration and water [23,24]. Ethanol acts as 
penetration enhancer and fluidizes the ethosomal lipids and 
stratum corneum bilayer, thus allowing the soft, malleable vesicles 
to penetrate the disorganized lipid bilayer. The high concentration 
of ethanol (20-50%) is the main reason for better skin permeation 
ability. Ethanol confers a surface negative net charge to ethosomes 
due to which size of vesicles decreases. Hence, size of ethosomal 
vesicles increases with decrease in concentration of ethanol [25]. 
Ethosomes can also be used for delivery of various antifungal 
agents (fluconazole) antiviral agents (zidovudine, lamivudine, 
stavudine, and acyclovir), NSAIDS (diclofenac, aceclofenac), 
antibiotics (erythromycin, cannabidol) and various other drugs like 
ammonium glycrrhizinate, salbutamol sulfate, propranolol, 
testosterone, finasteride, bacitracin, and methotrexate. These have 
shown the enhancement of pharmacological efficacy in drug 
targeting to transdermal and dermal sites for the treatment of 
various skin diseases [25-28].  
Sphingosomes 
Sphingosomes were introduced to overcome the stability problems 
of liposomes. These are so called due to the presence of 
sphingolipids instead of phospholipids present in liposomes. 
Phospholipids used in liposomes are prone to undergo chemical 
degradation such as oxidation and hydrolysis of ester linkage. The 
ether or amide linkage containing sphingolipids are found to be 
more stable than phospholipids as these are resistant to the 
chemical degradation [29]. Sphingosomes are efficient carrier for 
targeting of the drug to the site of action, because of being 
biodegradable, innocuous nature and identical to biological 
membrane. Sphingosomes provide selective passive targeting to 
tumour tissues and flexibly couple with site-specific ligands to 
achieve active targeting [30]. Sphingosomes are much more stable 
to acid hydrolysis and have better drug retention characteristics 
[29]. Sphingosomal products e.g., Marqibo(TM) (vincristine loaded 
sphingosomes) are loaded with active, cell cycle-specific 
anticancer agents that are benefited from increased targeting and 
long duration of drug exposure at the tumor site. Vincristine, 
vinorelbine and topotecan are approved cancer therapies which 
have been selected for sphingosomal formulation specifically for 
their ability to benefit from this novel encapsulation [30].  
Transferosomes 
The term transferosome was introduced in 1991 by GregorCevc. 
Transferosome means carrying body and is derived from Latin 
word ÂtransferreÊ means Âto carry acrossÊ and the Greek word 
ÂsomaÊ means ÂbodyÊ [31]. Transferosomes are such novel vesicular 
drug delivery systems whose uniqueness is an ultra deformable 
vesicle. It can squeeze itself through a pore, many times smaller 
than its size owing to its elasticity, designed to enhance the skin 
penetration and deliver the drug non-invasively through the skin 
barrier without measurable loss [31,32]. 
Transferosomes have been widely used as carrier for the 
controlled and targeted delivery of proteins, peptides, hormones 
and several drugs [33,34]. The oral delivery of peptides such as 
insulin and interferons, is impossible due to their instability and 
rapid degradation in the harsh environment of gastro intestinal 
tract. These are also difficult to diffuse through skin due to their 
large molecular weight, but these can be transported easily across 
the skin with the help of transferosomes. Transferosomes have 
also been used in transdermal immunization of tetanus toxoid and 
transcutaneous delivery of hepatitis-B vaccine [31]. Diclofenac 
loaded ultra-deformable vesicles have shown longer effect and 
reached in 10 timeÊs higher concentration in tissues under skin 
when compared with drug from commercial hydrogel [35]. Drugs 
can be readily targeted to peripheral tissues through 
transferosomes. Transferosomal formulations have been prepared 
for anti-HIV agents like zidovudine, indinavir and have been shown 
enhanced permeation through skin [31]. The ultra-deformable 
vesicles of ethinylestradiol have shown better anti-ovulatory effect 
as compared to plain drug for oral administration. Transferosomal 
formulation of local anaesthetics e.g. lidocaine and tetracaine 
induces topical anesthesia with less than 10 min with pain 
insensitivity as strong (80%) as that comparable with subcutaneous 
bolus injection, but the effect of transferosomal anaesthetic lasted 
for longer time [31,33]. 
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Table 3: Components used for the preparation of transferosomes  
S.No. Type of material Example Uses
1. Phospholipids Soya phosphatidyl choline, 
Dipalmitoylphosphatidyl choline, 
Distearoylphosphatidyl choline  
Vesicles forming component 
2. Surfactants Sodium cholate, Sodiumdeoxycholate, Span-
80, Tween-80 
For providing flexibility 
3. Alcohol Ethanol, Methanol As a solvent 
4. Buffering agent Saline Phosphate buffer(6.4) As a hydrating medium 
5. Dye Rhodamine-123, Fluorescein, Nile red For CSLM (confocal scanning laser 
microscopy) study 
 
Pharmacosomes 
Pharmacosomes are novel vesicular drug delivery systems having 
unique advantages over other drug delivery systems [36]. 
Pharmacosomes are amphiphilic lipoidal colloidal dispersions of 
drugs, covalently bound to lipids with potential to improve 
bioavailability of poorly water soluble as well as poorly lipophilic 
drugs [37]. Any drug possessing a free carboxyl group or an active 
hydrogen atom(-OH, -NH2) can be esterified (with or without a 
spacer group) to the hydroxyl group of a lipid molecule, thus 
generating an amphiphilic prodrug. An amphiphilic prodrug is then 
converted to pharmacosomes upon dilution with water. The 
prodrug conjoins hydrophilic and lipophilic properties (thereby 
acquiring amphiphilic characteristics), reduces interfacial tension, 
and at higher concentration exhibits mesomorphic behavior. 
Because of decrease in interfacial tension, the contact area 
increases, therefore bioavailability also increases [36].As the drug 
is covalently conjugated with lipids, loss due to leakage of drug 
does not occur. Hence, provides maximum entrapment efficiency. 
The three main components for the preparation of pharmacosomes 
are drug, solvent and lipid. Drug should contain active hydrogen 
atom (-COOH, OH, NH2), can be esterified with lipid and form 
amphiphilic complexes, which facilitate membrane transfer. The 
solvent should have high purity, volatility and intermediate polarity 
(between the polarity of phospholipid and drug) for the preparation 
of pharmacosomes. The most commonly used lipid for the 
preparation of pharmacosomesis phosphatidylcholine. The 
pharmacosomes can be prepared by hand-shaking and ether-
injection methods. These have been prepared for various non-
steroidal anti-inflammatory drugs, proteins, cardiovascular and 
antineoplastic drugs[36,38]. Ajay Semalty et al successfully 
prepared and evaluated of diclofenac loaded pharmacosomes to 
enhance the bioavailability and reduce the GI toxicity of drug [37]. 
AI Ping et al prepared didanosine loaded pharmacosomes for 
targeting to liver. They determined there in vivo behavior including 
liver targeting and sustained release at target site, in rats [39]. 
Zhang and Wang prepared 3ҩ,5ҩ-dioctanoyl-5-fluoro-2ҩ-deoxyuridine 
loaded pharmacosomes by central composite design showed good 
targeting efficiency in vivo and improved the ability of drug to cross 
the blood brain barrier [40]. 
Virosomes 
Virosomes are reconstituted viral envelopes that are composed of 
a lipid bilayer in which inserted viral glycoproteins can be derived 
from different enveloped viruses. Virosomes are described as 
liposomes with influenza virus hemagglutinin (HA) and 
neuraminidase (NA) spikes on their surface. Virosomes closely 
mimic the intact virus except that they do not contain virus 
replication machineries. They retain the cell entry and membrane 
fusion characteristics of the virus derived from. The two pathways 
by which reconstituted vesicles are able to enter the cells and 
deliver their contents into the cytoplasm are plasma membrane 
fusion(Sendai virus) and acid-induced fusion from within 
endosomes (Influenza virus). As a result, foreign substances 
encapsulated within the lumen of virosomes are effectively 
delivered to the cytosol of target cells. Virosomes can be used in 
vaccination for the efficient induction of antibody responses against 
the virus they are derived from [5]. 
 
Non-Lipoidal Biocarriers for Site-Specific Targeting 
Niosomes 
Handjanivila et al first reported the formation of vesicles on 
hydration of mixture of cholesterol and a single alkyl chain non-
ionic and non-toxic surfactant. Since then a number of non-ionic 
surfactants have been used to prepare vesicles e.g., polyglycerol 
alkyl ethers, glucosyldialkyl ethers, crown ethers, polyoxyethylene 
alkyl ethers, ester linked surfactants, steroid linked surfactant, brij 
and a series of spans and tweens. The resulting vesicles are 
termed as niosomes [41,42]. Niosomes or non-ionic surfactant 
vesicles are microscopic lamellar structure of size range 10-
1000nm consisting of spherical, uni or multilamellar and polyhedral 
vesicles in aqueous media. These also consist of inverse 
structures which appear only in non-aqueous media, formed by 
self-assembly of non-ionic surfactant and cholesterol with 
subsequent hydration [42-44]. The first report of non-ionic 
surfactant vesicles came from the cosmestic application devised by 
LÊOreal. Non-ionic surfactants are preferred due to less irritation 
power which decreases in the order of cationic, anionic, ampholytic 
and non-ionic surfactants respectively[45].  
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Niosomes as novel vesicular drug delivery system offer various 
advantages: 
Better patient compliance and better therapeutic effect in 
comparison to oily formulations [46]. 
Can be used to deliver hydrophilic, lipophilic as well as 
amphiphilic drugs and can accommodate drugs with wide range 
of solubility [47]. 
Controlled and sustained release of drugs due to depot 
formation [46]. 
Enhance the oral bioavailability of drugs [48]. 
Osmotically active and stable [48]. 
Biocompatible, biodegradable, non-toxic and non-immunogenic 
[44,48]. 
Protect the drug from enzymatic metabolism thus increases the 
stability of drug [44,46]. 
Drug targeting to various organs [46]. 
Enhance the skin permeation of drugs [46]. 
Easy tohandle, store and transport [46]. 
Administered by various routes via oral, parenteral, topical etc. 
[46] 
The shape, size, composition and fluidity of niosomes can be 
controlled as and when required [46]. 
Vanlerbeghe et al first reported the niosomes as an aspect of 
cosmetic industry [3]. Jain et al developed the niosomal gel for site 
specific sustained delivery of celecoxib. They found that the 
niosomal gel provided better skin permeation of drug as compared 
to carbopol gel [49]. Pei et al developed hydroxycamptothecin 
loaded PEGylated niosomes modified with transferrin for efficient 
tumour targeting [50]. Yong et al formulated and evaluated 
minoxidil niosomes for drug cutaneous targeting in treatment of 
skin diseases [51]. Lakshmi et al formulated salbutamol sulphate 
niosomes for lung targeting in the treatment of asthma [52]. Sathali 
et al formulated and evaluated terbinafine hydrochloride niosomes 
for targeting to fungal affected cells [53]. Hashim et al prepared 
and evaluated ribavirin niosomes for liver targeting for the 
treatment of chronic hepatitis C infection [54]. Malay K Das et al 
prepared rofecoxib niosomes for skin targeting for its sustained 
anti-inflammatory action [55].  The various other applications of 
niosomes for internal drug delivery and external drug delivery are 
discussed in table 4 and 5 respectively. 
Bilosomes 
Bilosomes are the novel innovative drug delivery carriers consist of 
deoxycholic acid incorporated into the membrane of niosomes [5]. 
As conventional vesicles (liposomes and niosomes) can cause 
dissolution and undergo enzymatic degradation in gastro intestinal 
tract but incorporation of bile salts (commonly used penetration 
enhancers) in niosomal formulation could stabilize the membrane 
against the detrimental effects of bile acids in GI tract [5,81]. These 
bile salt stabilized vesicles are known as bilosomes. These are 
highly biocompatible and have been found to improve the 
therapeutic efficacy of drugs due to their stability in gastro intestinal 
tract. Bilosomes have been found to increase the bioavailability of 
drugs as they can readily absorbed through small intestine to the 
portal circulation (hepatocirculation). Through this circulation they 
approach to liver and release the drug, so found to be an effective 
tool in drug targeting to liver [5,82]. Shukla et al showed that 
HBsAg loaded bilosomes produced both systemic as well as 
mucosal antibody responses upon oral administration [83]. For 
extended humoral, cell-mediated and mucosal immune responses, 
additional coating carrier system provided better protection against 
disease for longer period of time. Optimum mannan coating was 
found to stabilize the vesicles in gastrointestinal environment and 
also act as a targeting ligand for mannose receptors expressed on 
macrophages and dendritic cells [81]. 
Aquasomes 
Aquasomes firstly developed by Kossovsky, are one of the most 
recently developed delivery system for bioactive molecules [84]. 
Aquasomes are three layered structures (i.e. core, coating and 
drug) that are self-assembled through non covalent bonds, ionic 
bonds and vander waals forces [85]. They consist of tin oxide, 
nanocrystalline carbon ceramic (diamonds) or brushite (calcium 
phosphate dihydrate) core coated with oligomeric film to which 
biochemically active molecules are adsorbed by copolymerization, 
diffusion or adsorption with or without modification [86,88]. The 
solid core provides the structural stability, while the carbohydrate 
coating protects against dehydration and stabilizes the 
biochemically active molecules. Aquasomes are spherical 60-
300nm size particles called Âbodies of waterÊ. Their water like 
properties protects and preserves fragile biological molecules [86]. 
Mechanism of action of aquasomes is controlled by their surface 
chemistry, which deliver contents through combination of specific 
targeting, molecular shielding and slow and sustained release 
process. Due to their size and structural stability, these avoid 
clearance by reticuloendothelial system and degradation by other 
environmental changes [87]. Aquasomes can be used as red blood 
cell substitutes for the release of oxygen by haemoglobin. 
Aquasomes can be used as vaccines for delivery of viral antigen, 
for targeted intracellular gene therapy, for delivery of insulin and 
enzymes like DNAase and pigments/dyes [88]. 
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Table 4: For internal drug delivery by niosomes 
 
S.No. Application Drug used Non-ionic surfactant 
used 
Method Reference
1. Oral bioavailability 
enhancement 
Aceclofenac Span 20, 60 Ether injection technique [56]
  Acyclovir Span 60 Thin film hydration 
method 
[57]
  Cefuroxime axetil Span 40, 60, 80 Hand shaking method [58]
  Gliclazide Span 60 Thin film hydration 
method 
[59]
  Griseofulvin Span 20, 40, 60 Thin film hydration 
method,  
ether injection technique  
[60]
  Paclitaxel Tween 20, 60
Span 20, 40, 60 
Brij 72, 76, 78 
Thin film hydration 
method 
[61]
2. Cancer and 
atherosclerosis 
treatment 
β-carotene Span 40, 60, 80
Tween 20, 40, 60 
Thin film hydration 
method 
[62]
3. Reduce toxicity Cefpodoximeprox
etil 
Span 20, 40, 80 Thin film hydration 
method 
[63]
4. Stability improvement Fluconazole Span 60 Ether injection technique [64]
5. Tumour targeting Hydroxycamptothe
cin 
Span 60 Thin film hydration 
method, ultrasound 
method 
[50]
 
  Adiramycin Monoalkyltriglycerol 
ether 
Hand shaking technique, 
ether injection technique  
[55]
6. Treatment of 
tuberculosis 
Isoniazid Span 60 Ether injection method [66]
  Isoniazid Span 20, 60 Reverse phase 
evaporation method 
[67]
7. Antacid and antiulcer 
agent 
Lansoprazole Span 60 Reverse phase 
evaporation technique 
[68]
8. Anti-inflammatory 
activity 
Nimesulide Span 20, 40, 60 Thin film hydration 
method andether injection 
method 
[69]
9. Oral delivery of 
peptides 
Insulin  Brij 35, 52, 58, 72, 76, 
92, 97 
Thin film hydration 
method 
[70]
10. Treatment of 
tuberculosis along 
lymphatic system to 
prolong the release 
time 
Rifampicin Span 20, 40, 60, 80, 85 Reverse phase 
evaporation method 
[71]
11.  Liver targeting Ribavirin Span 60 Thin film hydration 
method 
[54]
12. Lung targeting Salbutamol 
sulphate 
Span 60 Thin film hydration 
method, 
Trans membrane pH 
gradient method 
[52]
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Table 5: For external drug delivery by niosomes 
S.No. Application Drug used Non-ionic surfactant 
used 
Method Reference
1. Ocular delivery to 
improve the low corneal 
penetration and 
bioavailability 
Acetazolamide Span 40, 60 Reverse phase 
evaporation, thin film 
hydration technique 
[72]
  Ofloxacin Span 60 Thin film hydration 
technique 
[73]
2. Prolong the drug release  Acyclovir Sorbitan 
monostearate 
Thin film hydration 
technique 
[74]
3. Ocular drug delivery for 
glaucoma treatment 
Brimonidinetartrate Span 20, 40, 60, 80 Thin film hydration 
technique 
[75]
4. Site specific sustained 
delivery in treatment of 
arthritis 
Celecoxib Span 60, 80 Thin film hydration 
technique 
[49]
5. Localized psoriasis 
treatment 
Dithranol Span 60 Thin film hydration 
technique 
[77]
6. Topical drug delivery 
carrier for treatment of 
cancer 
5-fluorouracil Bola surfactant, 
Span 80 
Thin film evaporation 
technique 
[78]
7. Transdermal drug 
delivery system 
Gallidermin Tween 61 Freeze dried method [79]
  Capsaicin Span 80,
 Tween 80 
Thin film hydration 
technique 
[76]
8. Anti-inflammatory activity Meloxicam Span 60, 80
Tween 60, 80 
Thin film hydration 
technique 
[80]
9. Improve skin permeation 
and bioavailability 
Minoxidil Brij 52, 76
Span 20, 40, 60, 80 
Thin film hydration 
technique 
[51]
10. Sustained therapeutic 
action 
Rofecoxib Span 20, 40, 60 Thin film hydration 
technique 
[55]
 
 
Conclusion 
Because of the site specific targeting of drugs and lots of other 
advantages, vesicular drug delivery system is gaining popularity in 
present scenario. Drugs can be directly targeted to their site of 
action to prevent toxic and undesired effects to other sites, further 
these can be used for bioavailability enhancement of the drugs, 
having poor bioavailability, to reduce the dose of drug administered 
and to enhance pharmacological action of drug. Vesicular system 
is valuable for drugs having narrow therapeutic index because 
targeting of drug to their site of action improves the overall 
pharmacokinetic and pharmacodynamic profile of drug and hence 
improvement in the overall therapy of the disease. Drugs can be 
successfully delivered using lipoidal biocarriers such as liposomes, 
enzymosomes, ethosomes, transferosomes, pharmacosomes, 
sphingosomes, virosomes, emulsomes and non lipoidal biocarriers 
such as niosomes, bilosomes and aquasomes as per the 
convenience of therapy. All these biocarriers have been reported 
for their successfully site specific targeting. 
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